Novel treatment for dermal lesions using a specific subpopulation of mesenchymal stem cells from human umbilical cords. In vivo assay in a murine model

PALMA MARÍA BELÉN; BUERO GUILLERMO; MIRIUKA SANTIAGO; ANDRINI LAURA; RICCILLO FERNANDO; LUZZANI CARLOS; PELINSKI PABLO; INDA ANA MARIA; CAROSSELLA EDGARDO; GARCIA MARCELA

Mar del Plata

Congreso; Reunion Anual de Sociedades de Biociencias SAIC-SAFE-SAB-SAP; 2019

SAIC-SAFE-SAB-SAP

The chronic venous ulcer (CVU) is described as the spontaneous or accidental tissue absence, in individuals with varicose leg, that can develop for more than fifteen days, with no signs of healing despite receiving conventional treatment. This inadequate and/or incomplete wound healing can lead to significant individual morbidity including a profound reduction in quality of life. In recent years, advances have been made, in particular, the use of stem cell-based therapies has been suggested. Mesenchymal stem cells (MSCs) have been examined in skin repair and regeneration after various acute and chronic skin injuries. All the treatments involve the utilization of autologous cells, which limits their application. The objective of this work were to develop a new treatment for CVU through the allogeneic application of differentiated mesenchymal cells (DMC), obtained from human umbilical cord Wharton?s jelly (ucMSC). We characterizated DMC by analyzing surface markers by flow cytometry. DMC possess immunomodulation capacity (by HLA-G expression, among others) allowing its allogeneic use. To check this, we realized an ex vivo assay of inhibition of activated lymphocytes proliferation exposed to DMCs. After that, we performed an in vivo assay, in mice, to evaluate the effect of DMC on the healing on the skin wounds, using DMC derived from murine or human umbilical cords. We have been able to isolate the cell population, the DMC, wich express HLA-G, and we tested its immunosuppressive function. In mice with dermal ulcers, we treated the injury with murine or human DMCs, and we observed that both groups healing more quickly than the control group (untreated), but unexpectedly, we noticed that when using human DMCs there was a 50% reduction in healing time. We developed the basis for a new method for the treatment of CVU through the allogeneic application of DMC from human ucMSC. These results made it possible to register a patent application with the European Patent Office.